RP-HPLC method for simultaneous determination of atenolol and indapamide in pharmaceutical dosage forms, human blood and milk

Thulasamma Parusu, Venkateswarlu Ponneri


A simple, sensitive and precise high performance liquid chromatographic method for the analysis of atenolol and indapamide with UV detection at 231 nm, has been developed, validated and used for the determination of these compounds in pharmaceutical dosage forms, in human blood and in human milk. The compounds were well separated on a Hypersil BDS C18 reversed-phase column with mobile phase consisting of, pH = 3.5, 0.01 M potassium dihydrogen orthophosphate buffer-acetonitrile (60:40; v:v) at a flow rate of 1.0 mL/min. The method showed good linearity in the range of 5-30 µg/mL for atenolol and 0.25-1.50 µg/mL for indapamide. Both the drugs were eluted within 5 minutes and give sharp peak with high theoretical plate count and low tailing factor. The reaction time for atenolol and indapamide was found to be 2.29 and 3.83 min, respectively. The validation was carried according to International Conference on Harmonisation (ICH) guidelines. In linearity curve correlation coefficients for atenolol and indapamide were found to be 0.9995 and 0.9991, respectively. The percent recovery was 99.81-100.02 for atenolol and indapamide indicating accuracy and reliability of method. So the method can be used for estimation of these drugs in tablet dosage form, human blood and milk.




Atenolol; RP-HPLC; Indapamide; Human milk; Human blood; Formulations

European Journal of Chemistry, 3 (2), (2012), 138-142

Full Text:

PDF    /    /

DOI: http://dx.doi.org/10.5155/eurjchem.3.2.138-142.537


[1]. Reynolds, J. E. F. In; Martindale, The Extra Pharmacopeia, 31st Edition, Royal Pharmaceutical society, London, 1996, 827.

[2]. McGuiness, M. D. M.; Roy, M. D.; Deng, M. D. J. J. Am. Acc. Derm. 1997, 37, 298-299.

[3]. United States Pharmacopeia: USP 26 the national formulary USP 26-NF1, twenty sixth ed. Rockville, MD, 2003.

[4]. British Pharmacopoeia Londom: The Stationer Office, 2001, v. 2.

[5]. Agrawal, Y. K.; Raman, K.; Raiput, S.; Menon, S. K. Anal. Lett. 1992, 12, 1503-1520.

[6]. Golcu, A.; Yucesoy, C.; Serin, S. Il Farmaco 2004, 59(6), 487-492.

[7]. Salem, H. J. Pharm. Biomed. Anal. 2002, 29, 527-538.

[8]. Al-Ghannam, S. M.; Belal, F. J. Aoac Int. 2002, 85(4), 817-823.

[9]. Amin, A. S.; Ragab, G. H.; Saleh, H. J. Pharm. Biomed. Anal. 2002, 30, 1347-1353.

[10]. Al-Ghannam, S. M. J. Pharm. Biomed. Anal. 2006, 40, 151-156.

[11]. Ferraro, M. C. F.; Castellano, P. M.; Kaufman, T. S. J. Pharm. Biomed. Anal. 2004, 34, 305-314

[12]. Bonazzi, D.; Gotti, R.; Andrisano, V.; Cavrini, V. Il Farmaco 1996, 51(11), 733-738.

[13]. Martinez, I. R.; Coque, M. C. G. A.; Camanas, R. M. V. J. Chromatogr. A. 1997, 765, 221-231.

[14]. Argekar, A. P.; Sawant, J. G. J. Liq. Chromatogr. Rel. Technol. 1999, 22, 1571-1578.

[15]. Argekar, A. P.; Powar, S. G. J Pharm Biomed Anal, 2000, 21(6), 1137-1142.

[16]. Nikolelis, D. P.; Petropoulou, S. E.; Mitrokotsa, M. V. Bioelectrochemistry, 2002, 58(1), 107-112.

[17]. Hassan, S. S. M.; Abou-Sekkina, M. M.; El-Ries, M. A.; Wassel, A. A. J. Pharm. Biomed. Anal. 2003, 32, 175-180.

[18]. Shamsipur, M.; Jalali, F. Anal. Lett. 2005, 38, 401-410.

[19]. Bonato, P. S.; Briguenti, A. C. C. Drug Dev. Ind. Pharm. 2005, 31, 209-214.

[20]. Shafaati, A.; Clark, B. J. Pharm. Biomed. Anal. 1996, 14(11), 1547-1554.

[21]. Maguregui, M. I.; Jimenez, R. M.; Alonso, R. M. J. Chromatogr. Sci. 1998, 36(10), 516-522.

[22]. Goyal, R. N.; Gupta, V. K.; Oyama, M.; Bachheti, N. Electrochem. Commun. 2006, 8, 65-70.

[23]. Goyal, R. N.; Singh, S. P. Talanta 2006, 39, 932-937.

[24]. Sweetman S. C. In Martindale: The complete Drug Reference, 33rd edition, Pharmaceutical Press, London, 2002, pp. 913.

[25]. ONeil, M. J.; Smith, A.; Heckelman, P. E.; Kinneary, J. F. The Merk Index, an Encyclopedia of Chemicals, Drugs and Biologicals. Merck and Co. Inc., 12th edition, White House Station, New Jersey, 1996, pp. 848.

[26]. Agrawal, Y. K.; Majumdar, F. D. Anal Lett. 1995, 28, 1691-1702.

[27]. Ebeid, M. Y.; Moussa, B. A.; Nasr, A. A.; Ashour, F. A, Malek A. A. Egypt J. Pharm. Sci. 1994, 35, 587-594.

[28]. Padval, M. V.; Bhargava, H. N. J. Pharm. Biomed. Anal. 1993, 11, 1033-1041.

[29]. Miller, R. B.; Dadgar, D.; Lalande, M. J. Chromatogr. B 1993, 614, 293-300.

[30]. British Pharmacopoeia. BritishPharmacopoeial Commission office, London, U. K. 2007; vol. II: 1078-1080.

[31]. British Pharmacopoeia. BritishPharmacopoeial Commission office, London, U. K. 2007; vol. II: 2665-2666.

[32]. The United States of Pharmacopoeia-30/National Formulary-25. Asian Edition United States Pharmacopoeial Convention, Inc., Rockville MD. 2007; vol. II: 2340.

[33]. The United States of Pharmacopoeia-30/National Formulary-25. Asian Edition United States Pharmacopoeial Convention, Inc., Rockville MD. 2007; vol. II: 2341.

[34]. ICH, Q2A Text on validation of analytical procedures; International conference on Harmonization, 1994.

[35]. ICH, Q3B validation of analytical procedures Methodology, International conference on Harmonization, 1996.

[36]. Shah, V. P.; Midha, K. K.; Dighe, S.; Megilveray, L. J.; Skelly, J. P.; Jacobi, A. J. Pharm. Sci. 1992, 81, 309-312.

[37]. Roosi, D. T.; Wright, D. S. J. Pharm. Biomed. Anal. 1997, 15, 495-504.

[38]. ICH topic Q2A, validation of analytical procedures: Methodology. CPMP/ICH/281/95.

[39]. Yeniceli, D.; Dogrukol, A. K.; Tuncel, M. J. Pharm. Biomed. Anal. 2006, 40, 197-201.


  • There are currently no refbacks.